<ul>
<li>想知道 Teva Pharmaceutical Industries 当前价格约为 35.35 美元是否仍然具有价值，还是大部分机会已经反映在价格中？本文将分析当前估值信号的真实含义。</li>
<li>该股票在过去一周的回报率为 13.1%，过去一个月为 17.5%，年初至今为 14.2%，过去一年为 115.7%，并且在过去三年和五年内分别获得了非常大的收益，分别为 244.9%，这自然引发了关于当前水平的风险和回报的问题。</li>
<li>最近对 Teva 的报道集中在其作为大型仿制药生产商的进展以及其当前资本结构的影响，为投资者提供了市场如何看待该股票的新背景。其他评论则强调了与医疗需求相关的公司的持续关注，这可能会影响投资者对 Teva 长期前景和风险特征的看法。</li>
<li>即使在这些变动之后，Teva 目前的价值评分为 2/6。接下来的讨论将比较不同的估值方法，并最终以更全面的方式思考该股票可能的价值。</li>
</ul>
<p>Teva Pharmaceutical Industries 在我们的估值检查中仅得分 2/6。查看我们在完整估值分析中发现的其他警示信号。</p>
<h3>方法 1：Teva Pharmaceutical Industries 折现现金流 (DCF) 分析</h3>
<p>折现现金流（DCF）模型通过预测公司的未来现金流并将其折现回今天的价值，来估计股票的潜在价值。</p>
<p>对于 Teva Pharmaceutical Industries，使用的模型是基于现金流预测的两阶段自由现金流到股权的方法。最新的十二个月自由现金流约为 11.7 亿美元。分析师的预测和后续推算表明，到 2030 年年自由现金流将达到约 40.4 亿美元，2026 年和 2027 年的中期预测分别为 22.1 亿美元和 30.2 亿美元。Simply Wall St 在可用时使用分析师的估计，然后用自己的增长假设延伸系列，以完成 10 年的路径。</p>
<p>折现这一系列预测的现金流，估计每股内在价值约为 58.44 美元。与最近的股价约 35.35 美元相比，该模型表明股票在此基础上被低估了约 39.5%。</p>
<p><strong>结果：被低估</strong></p>
<p>我们的折现现金流 (DCF) 分析表明 Teva Pharmaceutical Industries 被低估了 39.5%。将其添加到您的关注列表或投资组合中，或发现 48 只其他高质量被低估的股票。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/62486a02-b6f5-48a5-8ffa-0d95e668a50d/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTA1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/62486a02-b6f5-48a5-8ffa-0d95e668a50d/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTA1"/></p>
<p>截至 2026 年 5 月的 TEVA 折现现金流</p>
<p>前往我们公司报告的估值部分，了解我们如何得出 Teva Pharmaceutical Industries 的公允价值的更多细节。</p>
<h3>方法 2：Teva Pharmaceutical Industries 价格与收益</h3>
<p>对于一家盈利的企业，市盈率是查看每美元收益支付多少的简单方法。这使其成为与 DCF 模型的有用交叉检查。什么算作 “正常” 的市盈率取决于市场对公司增长前景和风险的看法，预期增长较高和感知风险较低通常与更高的倍数相对应。</p>
<p>Teva Pharmaceutical Industries 当前的市盈率为 26.30 倍。这高于制药行业平均水平约 16.92 倍，也高于同行平均水平 20.52 倍，这表明该股票的定价相对于许多行业同行而言是溢价的。Simply Wall St 为 Teva 提供的公允比率为 21.55 倍，这是其模型基于收益增长、利润率、行业、市场资本和公司特定风险等因素建议的市盈率水平。</p>
<p>公允比率比简单的同行或行业比较更有用，因为它调整了 Teva 自身的特征，而不是假设该行业的所有公司都应以相同的倍数交易。由于实际市盈率高于公允比率，该股票目前被认为交易价格高于该框架所暗示的水平。</p>
<p><strong>结果：被高估</strong></p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/62486a02-b6f5-48a5-8ffa-0d95e668a50d/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTA1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/62486a02-b6f5-48a5-8ffa-0d95e668a50d/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTA1"/></p>
<p>截至 2026 年 5 月的 NYSE:TEVA 市盈率</p>
<p>市盈率讲述了一个故事，但如果真正的机会在其他地方呢？开始投资于遗产，而不是高管。发现我们 17 家顶级创始人领导的公司。</p>
<h3>升级您的决策：选择您的 Teva Pharmaceutical Industries 故事</h3>
<p>之前提到过，有一种更好的理解估值的方法，因此在这里引入叙述，作为您将对公司故事与公允价值、未来收入、收益和利润率的数字进行关联的简单方式，然后查看该故事如何转化为财务预测和股票的隐含价值。</p>
<p>在 Simply Wall St，叙述位于社区页面，让您选择或构建一个视图，将 Teva Pharmaceutical Industries 当前的业务组合、管道、资产负债表和风险与特定假设联系起来，例如更谨慎的公允价值约为 21.53 美元或更乐观的观点约为 45.00 美元，这两者都是基于对未来收益、利润率和市盈率倍数的不同预期。</p>
<p>通过将所选叙述的公允价值与当前股价进行比较，您可以快速查看该故事是否暗示股票在您的假设下是便宜还是昂贵。由于当新信息（如收益结果或新闻）添加到平台时，叙述会被刷新，因此您选择的故事和隐含估值将与最新数据保持一致，而无需您额外的工作。</p>
<p>然而，对于 Teva Pharmaceutical Industries，我们将通过预览两个领先的 Teva Pharmaceutical Industries 叙述来为您提供便利：</p>
<p><strong>🐂 Teva Pharmaceutical Industries 看涨案例</strong></p>
<p>在这个看涨叙述中的公允价值：40.09 美元</p>
<p>在最近的 35.35 美元价格下，与公允价值的差距：约低于叙述公允价值的 11.8%</p>
<p>分析师在此观点中使用的收入增长输入：135.0%</p>
<ul>
<li>该观点依赖于广泛的产品组合、更高利润率的品牌产品和生物仿制药作为未来收益的主要驱动力，得益于成本节约和现代化。</li>
<li>假设到 2029 年收入为 181 亿美元，收益为 23 亿美元，利润率上升，并对这些收益应用 26.6 倍的市盈率。</li>
<li>该故事中的主要警示是对少数品牌药物的依赖、较大的债务负担、监管和定价风险，以及在管道和生物仿制药推出方面需要顺利执行。</li>
</ul>
<p><strong>🐻 泰瓦制药的熊市案例</strong></p>
<p>在这个悲观叙述中的公允价值：21.53 美元</p>
<p>在最近的 35.35 美元价格下，与公允价值的差距：约高于叙述公允价值的 64.2%</p>
<p>悲观分析师在此观点中使用的收入增长输入：100.5%</p>
<ul>
<li>该观点关注于对一小部分增长驱动因素的依赖、仿制药和生物仿制药的定价压力，以及对成本节约和供应链变化的不确定性。</li>
<li>假设中期改善较为温和，到 2028 年收入约为 173 亿美元，收益为 16 亿美元，并对这些收益应用 20.7 倍的较低市盈率。</li>
<li>这种谨慎立场的风险包括品牌产品、晚期管道和成本项目可能支持比悲观情景更强的利润率和收益。</li>
</ul>
<p>如果您想查看这两个故事以及其他故事是如何逐行构建完整的财务预测的，可以查看社区对泰瓦的观点，并跟踪随着新数据的到来它们如何变化。要查看这些结果如何与长期增长、风险和估值相关，请查看 Simply Wall St 上泰瓦制药的完整社区叙述范围。将公司添加到您的关注列表或投资组合中，以便在故事发展时收到提醒。</p>
<p>您认为泰瓦制药的故事还有更多内容吗？前往我们的社区看看其他人怎么说！</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/62486a02-b6f5-48a5-8ffa-0d95e668a50d/chart/quote-price/query-ZGF0ZT0yMDI2LTA1LTA1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/62486a02-b6f5-48a5-8ffa-0d95e668a50d/chart/quote-price/query-ZGF0ZT0yMDI2LTA1LTA1"/></p>
<p>NYSE:TEVA 1 年股票价格走势图</p>
<p><em>这篇文章来自 Simply Wall St，性质一般。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 对提到的任何股票没有持仓。</em></p>
<h3>估值是复杂的，但我们在这里为您简化。</h3>
<p>通过我们的详细分析，发现泰瓦制药是否可能被低估或高估，分析内容包括 <strong>公允价值估算、潜在风险、股息、内部交易及其财务状况。</strong></p>
<p>获取免费分析</p>

梯瓦制药

美国制药 ETF - iShares

<p>梯瓦制药 (Teva Pharmaceutical Industries, TEVA) 目前的价格约为 $35.35，这引发了人们对其估值的质疑，因为过去一年其股票大幅上涨。折现现金流 (DCF) 分析表明，该股票被低估了 39.5%，估计每股内在价值为 $58.44。然而，其市盈率为 26.30 倍，超过行业平均水平，表明与同行相比可能被高估。文章讨论了各种估值方法，并强调了理解公司长期前景和风险特征的重要性</p>

<ul>
<li>Wondering if Teva Pharmaceutical Industries at around US$35.35 is still offering value or if most of the opportunity has already been reflected in the price? This article breaks down what the current valuation signals are really saying.</li>
<li>The stock has posted returns of 13.1% over the past week, 17.5% over the last month, 14.2% year to date and 115.7% over the past year, with a very large 3 year gain and a 244.9% 5 year return that naturally raise questions about risk and reward at today’s level.</li>
<li>Recent coverage on Teva has focused on its progress as a large generic drug producer and the implications of its current capital structure, giving investors fresh context for how the market is treating the stock. Other commentary has highlighted ongoing interest in companies linked to healthcare demand, which can influence how investors view Teva’s long term prospects and risk profile.</li>
<li>Even after these moves, Teva currently has a value score of 2/6. The discussion ahead will compare different valuation methods and then finish with a more rounded way to think about what the stock might be worth.</li>
</ul>
<div class="lb-trans"><ul>
<li>想知道 Teva Pharmaceutical Industries 当前价格约为 35.35 美元是否仍然具有价值，还是大部分机会已经反映在价格中？本文将分析当前估值信号的真实含义。</li>
<li>该股票在过去一周的回报率为 13.1%，过去一个月为 17.5%，年初至今为 14.2%，过去一年为 115.7%，并且在过去三年和五年内分别获得了非常大的收益，分别为 244.9%，这自然引发了关于当前水平的风险和回报的问题。</li>
<li>最近对 Teva 的报道集中在其作为大型仿制药生产商的进展以及其当前资本结构的影响，为投资者提供了市场如何看待该股票的新背景。其他评论则强调了与医疗需求相关的公司的持续关注，这可能会影响投资者对 Teva 长期前景和风险特征的看法。</li>
<li>即使在这些变动之后，Teva 目前的价值评分为 2/6。接下来的讨论将比较不同的估值方法，并最终以更全面的方式思考该股票可能的价值。</li>
</ul>
</div><p>Teva Pharmaceutical Industries scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.</p>
<div class="lb-trans"><p>Teva Pharmaceutical Industries 在我们的估值检查中仅得分 2/6。查看我们在完整估值分析中发现的其他警示信号。</p>
</div><h3>Approach 1: Teva Pharmaceutical Industries Discounted Cash Flow (DCF) Analysis</h3>
<div class="lb-trans"><h3>方法 1：Teva Pharmaceutical Industries 折现现金流 (DCF) 分析</h3>
</div><p>A Discounted Cash Flow, or DCF, model estimates what a stock might be worth by projecting the company’s future cash flows and then discounting those back to today’s value using a required rate of return.</p>
<div class="lb-trans"><p>折现现金流（DCF）模型通过预测公司的未来现金流并将其折现回今天的价值，来估计股票的潜在价值。</p>
</div><p>For Teva Pharmaceutical Industries, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month free cash flow is about $1.17b. Analyst forecasts and subsequent extrapolations indicate annual free cash flows reaching about $4.04b by 2030, with interim projections such as $2.21b in 2026 and $3.02b in 2027. Simply Wall St uses analyst estimates where available and then extends the series with its own growth assumptions to complete the 10 year path.</p>
<div class="lb-trans"><p>对于 Teva Pharmaceutical Industries，使用的模型是基于现金流预测的两阶段自由现金流到股权的方法。最新的十二个月自由现金流约为 11.7 亿美元。分析师的预测和后续推算表明，到 2030 年年自由现金流将达到约 40.4 亿美元，2026 年和 2027 年的中期预测分别为 22.1 亿美元和 30.2 亿美元。Simply Wall St 在可用时使用分析师的估计，然后用自己的增长假设延伸系列，以完成 10 年的路径。</p>
</div><p>Discounting this stream of projected cash flows results in an estimated intrinsic value of about $58.44 per share. Compared with the recent share price of around $35.35, the model suggests the stock is about 39.5% undervalued on this basis.</p>
<div class="lb-trans"><p>折现这一系列预测的现金流，估计每股内在价值约为 58.44 美元。与最近的股价约 35.35 美元相比，该模型表明股票在此基础上被低估了约 39.5%。</p>
</div><p><strong>Result: UNDERVALUED</strong></p>
<div class="lb-trans"><p><strong>结果：被低估</strong></p>
</div><p>Our Discounted Cash Flow (DCF) analysis suggests Teva Pharmaceutical Industries is undervalued by 39.5%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.</p>
<div class="lb-trans"><p>我们的折现现金流 (DCF) 分析表明 Teva Pharmaceutical Industries 被低估了 39.5%。将其添加到您的关注列表或投资组合中，或发现 48 只其他高质量被低估的股票。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/62486a02-b6f5-48a5-8ffa-0d95e668a50d/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTA1" alt="" original-src="https://images.simplywall.st/company/62486a02-b6f5-48a5-8ffa-0d95e668a50d/chart/dcf?date=2026-05-05"/></p>
<p>TEVA Discounted Cash Flow as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 TEVA 折现现金流</p>
</div><p>Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Teva Pharmaceutical Industries.</p>
<div class="lb-trans"><p>前往我们公司报告的估值部分，了解我们如何得出 Teva Pharmaceutical Industries 的公允价值的更多细节。</p>
</div><h3>Approach 2: Teva Pharmaceutical Industries Price vs Earnings</h3>
<div class="lb-trans"><h3>方法 2：Teva Pharmaceutical Industries 价格与收益</h3>
</div><p>For a profitable business, the P/E ratio is a straightforward way to see how much you are paying for each dollar of earnings. This makes it a useful cross check against a DCF model. What counts as a “normal” P/E depends on how the market views a company’s growth prospects and risk, with higher expected growth and lower perceived risk usually lining up with a higher multiple.</p>
<div class="lb-trans"><p>对于一家盈利的企业，市盈率是查看每美元收益支付多少的简单方法。这使其成为与 DCF 模型的有用交叉检查。什么算作 “正常” 的市盈率取决于市场对公司增长前景和风险的看法，预期增长较高和感知风险较低通常与更高的倍数相对应。</p>
</div><p>Teva Pharmaceutical Industries currently trades on a P/E of 26.30x. That is above the Pharmaceuticals industry average of about 16.92x and also higher than the peer group average of 20.52x, which suggests the stock is priced at a premium compared with many sector peers. Simply Wall St’s Fair Ratio for Teva is 21.55x, which is the P/E level its model suggests based on factors like earnings growth, profit margins, industry, market cap and company specific risks.</p>
<div class="lb-trans"><p>Teva Pharmaceutical Industries 当前的市盈率为 26.30 倍。这高于制药行业平均水平约 16.92 倍，也高于同行平均水平 20.52 倍，这表明该股票的定价相对于许多行业同行而言是溢价的。Simply Wall St 为 Teva 提供的公允比率为 21.55 倍，这是其模型基于收益增长、利润率、行业、市场资本和公司特定风险等因素建议的市盈率水平。</p>
</div><p>The Fair Ratio can be more useful than a simple peer or industry comparison because it adjusts for Teva’s own characteristics rather than assuming all companies in the sector should trade on the same multiple. With the actual P/E above the Fair Ratio, the stock currently screens as trading richer than what this framework would imply.</p>
<div class="lb-trans"><p>公允比率比简单的同行或行业比较更有用，因为它调整了 Teva 自身的特征，而不是假设该行业的所有公司都应以相同的倍数交易。由于实际市盈率高于公允比率，该股票目前被认为交易价格高于该框架所暗示的水平。</p>
</div><p><strong>Result: OVERVALUED</strong></p>
<div class="lb-trans"><p><strong>结果：被高估</strong></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/62486a02-b6f5-48a5-8ffa-0d95e668a50d/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTA1" alt="" original-src="https://images.simplywall.st/company/62486a02-b6f5-48a5-8ffa-0d95e668a50d/chart/pe-multiple-vs-industry?date=2026-05-05"/></p>
<p>NYSE:TEVA P/E Ratio as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 NYSE:TEVA 市盈率</p>
</div><p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 17 top founder-led companies.</p>
<div class="lb-trans"><p>市盈率讲述了一个故事，但如果真正的机会在其他地方呢？开始投资于遗产，而不是高管。发现我们 17 家顶级创始人领导的公司。</p>
</div><h3>Upgrade Your Decision Making: Choose your Teva Pharmaceutical Industries Narrative</h3>
<div class="lb-trans"><h3>升级您的决策：选择您的 Teva Pharmaceutical Industries 故事</h3>
</div><p>Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple way for you to attach a story, your view on a company, to the numbers you see for fair value, future revenue, earnings and margins, and then see how that story translates into a financial forecast and an implied value for the stock.</p>
<div class="lb-trans"><p>之前提到过，有一种更好的理解估值的方法，因此在这里引入叙述，作为您将对公司故事与公允价值、未来收入、收益和利润率的数字进行关联的简单方式，然后查看该故事如何转化为财务预测和股票的隐含价值。</p>
</div><p>On Simply Wall St, Narratives sit in the Community page and let you pick or build a view that links Teva Pharmaceutical Industries current business mix, pipeline, balance sheet and risks to specific assumptions, such as the more cautious fair value around US$21.53 or the more optimistic view around US$45.00, both of which are based on different expectations for future earnings, profit margins and P/E multiples.</p>
<div class="lb-trans"><p>在 Simply Wall St，叙述位于社区页面，让您选择或构建一个视图，将 Teva Pharmaceutical Industries 当前的业务组合、管道、资产负债表和风险与特定假设联系起来，例如更谨慎的公允价值约为 21.53 美元或更乐观的观点约为 45.00 美元，这两者都是基于对未来收益、利润率和市盈率倍数的不同预期。</p>
</div><p>By comparing the Fair Value from a chosen Narrative with the current share price, you can quickly see whether that story implies the stock is cheap or expensive on your assumptions. Because Narratives are refreshed when new information such as earnings results or news is added to the platform, your chosen story and the implied valuation stay aligned with the latest data without extra work on your side.</p>
<div class="lb-trans"><p>通过将所选叙述的公允价值与当前股价进行比较，您可以快速查看该故事是否暗示股票在您的假设下是便宜还是昂贵。由于当新信息（如收益结果或新闻）添加到平台时，叙述会被刷新，因此您选择的故事和隐含估值将与最新数据保持一致，而无需您额外的工作。</p>
</div><p>For Teva Pharmaceutical Industries, however, we will make it really easy for you with previews of two leading Teva Pharmaceutical Industries Narratives:</p>
<div class="lb-trans"><p>然而，对于 Teva Pharmaceutical Industries，我们将通过预览两个领先的 Teva Pharmaceutical Industries 叙述来为您提供便利：</p>
</div><p><strong>🐂 Teva Pharmaceutical Industries Bull Case</strong></p>
<div class="lb-trans"><p><strong>🐂 Teva Pharmaceutical Industries 看涨案例</strong></p>
</div><p>Fair value in this bullish Narrative: US$40.09</p>
<div class="lb-trans"><p>在这个看涨叙述中的公允价值：40.09 美元</p>
</div><p>Gap to this fair value at the recent US$35.35 price: about 11.8% below the Narrative fair value</p>
<div class="lb-trans"><p>在最近的 35.35 美元价格下，与公允价值的差距：约低于叙述公允价值的 11.8%</p>
</div><p>Analyst revenue growth input used in this view: 135.0%</p>
<div class="lb-trans"><p>分析师在此观点中使用的收入增长输入：135.0%</p>
</div><ul>
<li>This view leans on a broad portfolio, higher margin branded products, and biosimilars as the main engines for future earnings, supported by cost savings and modernization.</li>
<li>It builds in assumptions for revenue of US$18.1b and earnings of US$2.3b by 2029, with profit margins rising and a P/E of 26.6x applied to those earnings.</li>
<li>Key cautions in this story are reliance on a handful of branded drugs, a sizeable debt load, regulatory and pricing risks, and the need for smooth execution on the pipeline and biosimilar launches.</li>
</ul>
<div class="lb-trans"><ul>
<li>该观点依赖于广泛的产品组合、更高利润率的品牌产品和生物仿制药作为未来收益的主要驱动力，得益于成本节约和现代化。</li>
<li>假设到 2029 年收入为 181 亿美元，收益为 23 亿美元，利润率上升，并对这些收益应用 26.6 倍的市盈率。</li>
<li>该故事中的主要警示是对少数品牌药物的依赖、较大的债务负担、监管和定价风险，以及在管道和生物仿制药推出方面需要顺利执行。</li>
</ul>
</div><p><strong>🐻 Teva Pharmaceutical Industries Bear Case</strong></p>
<div class="lb-trans"><p><strong>🐻 泰瓦制药的熊市案例</strong></p>
</div><p>Fair value in this bearish Narrative: US$21.53</p>
<div class="lb-trans"><p>在这个悲观叙述中的公允价值：21.53 美元</p>
</div><p>Gap to this fair value at the recent US$35.35 price: about 64.2% above the Narrative fair value</p>
<div class="lb-trans"><p>在最近的 35.35 美元价格下，与公允价值的差距：约高于叙述公允价值的 64.2%</p>
</div><p>Bearish analyst revenue growth input used in this view: 100.5%</p>
<div class="lb-trans"><p>悲观分析师在此观点中使用的收入增长输入：100.5%</p>
</div><ul>
<li>This view focuses on dependence on a narrow set of growth drivers, pressure on pricing in generics and biosimilars, and uncertainty around cost savings and supply chain changes.</li>
<li>It assumes more modest medium term improvements, with revenue of about US$17.3b and earnings of US$1.6b by 2028, and a lower P/E of 20.7x applied to those earnings.</li>
<li>Risks to this cautious stance include the possibility that branded products, the late stage pipeline, and cost programs support stronger margins and earnings than the bearish scenario allows for.</li>
</ul>
<div class="lb-trans"><ul>
<li>该观点关注于对一小部分增长驱动因素的依赖、仿制药和生物仿制药的定价压力，以及对成本节约和供应链变化的不确定性。</li>
<li>假设中期改善较为温和，到 2028 年收入约为 173 亿美元，收益为 16 亿美元，并对这些收益应用 20.7 倍的较低市盈率。</li>
<li>这种谨慎立场的风险包括品牌产品、晚期管道和成本项目可能支持比悲观情景更强的利润率和收益。</li>
</ul>
</div><p>If you want to see how these two stories and others are built line by line into full financial forecasts, you can review the community views on Teva and track how they change as new data comes in by heading to the To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Teva Pharmaceutical Industries on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.</p>
<div class="lb-trans"><p>如果您想查看这两个故事以及其他故事是如何逐行构建完整的财务预测的，可以查看社区对泰瓦的观点，并跟踪随着新数据的到来它们如何变化。要查看这些结果如何与长期增长、风险和估值相关，请查看 Simply Wall St 上泰瓦制药的完整社区叙述范围。将公司添加到您的关注列表或投资组合中，以便在故事发展时收到提醒。</p>
</div><p>Do you think there's more to the story for Teva Pharmaceutical Industries? Head over to our Community to see what others are saying!</p>
<div class="lb-trans"><p>您认为泰瓦制药的故事还有更多内容吗？前往我们的社区看看其他人怎么说！</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/62486a02-b6f5-48a5-8ffa-0d95e668a50d/chart/quote-price/query-ZGF0ZT0yMDI2LTA1LTA1" alt="" original-src="https://images.simplywall.st/company/62486a02-b6f5-48a5-8ffa-0d95e668a50d/chart/quote-price?date=2026-05-05"/></p>
<p>NYSE:TEVA 1-Year Stock Price Chart</p>
<div class="lb-trans"><p>NYSE:TEVA 1 年股票价格走势图</p>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章来自 Simply Wall St，性质一般。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 对提到的任何股票没有持仓。</em></p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值是复杂的，但我们在这里为您简化。</h3>
</div><p>Discover if Teva Pharmaceutical Industries might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通过我们的详细分析，发现泰瓦制药是否可能被低估或高估，分析内容包括 <strong>公允价值估算、潜在风险、股息、内部交易及其财务状况。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>获取免费分析</p>
</div>

在梯瓦制药（TEVA）经历了多年强劲上涨后，现在重新评估是否为时已晚？